Combination therapy of proliferative diabetic retinopathy using the Russian biosimilar ranibizumab
https://doi.org/10.21516/2072-0076-2025-18-3-113-120
Abstract
Proliferative diabetic retinopathy (PDR) is one of the main causes of vision loss in diabetes mellitus. Panretinal laser photocoagulation (PRP) remains one of the main methods of treating the proliferative process in diabetic retinal damage. In 2018, a prospective randomized multicenter open-label PROTEUS study demonstrated higher efficacy of PRP in combination with intravitreal ranibizumab compared to PRP alone in the treatment of patients with high-risk PDR. This article presents three clinical cases of combination therapy for proliferative diabetic retinopathy using a Russian biosimilar of ranibizumab in patients with type 1 diabetes mellitus.
About the Authors
A. I. Malakhova
Smolensk Regional Clinical Hospital
Russian Federation
Russian Federation
Anna I. Malakhova — Cand. of Med. Sci., ophthalmologist
27, Gagarina Aven, Smolensk, 214018
A. A. Bystrevskaya
Smolensk State Medical University
Russian Federation
Russian Federation
Anna A. Bystrevskaya — Cand. of Med. Sci., associate professor, chair of eye diseases
28, Krupskaya St., Smolensk, 214019
References
1. Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020; 127 (1): P66–P145. doi: 10.1016/j.ophtha.2019.09.025
2. Neroev V.V., Zaitseva O.V., Mikhailova L.A. Prevalence of diabetic retinopathy in the Russian Federation according to federal statistics. Russian ophthalmological journal. 2023; 16 (3): 7–11 (In Russ.). https://doi.org/10.21516/2072-0076-2023-16-3-7-11
3. Neroev V.V. Diagnostics and treatment of diabetic retinopathy and diabetic macular edema. Russian ophthalmological journal. 2014; 7 (3): 71–84 (In Russ.).
4. Williams R, Airey M, Baxter H, et al. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond). 2004; 18 (10): 963–83. doi: 10.1038/sj.eye.6701476
5. Sabanayagam C, Banu R, Chee ML, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol. 2019 Feb; 7 (2): 140–9. doi: 10.1016/S2213-8587(18)30128-1
6. Le NT, Kroeger ZA, Lin WV, Khanani AM, Weng CY. Novel treatments for diabetic macular edema and proliferative diabetic retinopathy. Curr Diab Rep. 2021; 21 (10): 43. doi: 10.1007/s11892-021-01412-5
7. Crabtree GS, Chang JS. Management of complications and vision loss from proliferative diabetic retinopathy. Curr Diab Rep. 2021; 21 (9): 33. doi: 10.1007/s11892-021-01396-2
8. Demir G, Arici M, Alkin Z. Preoperative evaluation of tractional retinal detachment with b-mode ultrasonography in diabetic vitreous hemorrhage. Beyoglu Eye J. 2021; 6 (1): 49–53. doi: 10.14744/bej.2021.58561
9. Wang Q, Zhao J, Xu Q, et al. Visual outcomes and complications following one-way air-fluid exchange technique for vitreous hemorrhage post vitrectomy in proliferative diabetic retinopathy patients. BMC Ophthalmol. 2021; 21 (1): 129. doi: 10.1186/s12886-021-01885-8
10. Figueira J, Fletcher E, Massin P, et al; EVICR.net Study Group. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study). Ophthalmology. 2018; 125 (5): 691–700. doi: 10.1016/j.ophtha.2017.12.008
11. Bhatwadekar AD, Shughoury A, Belamkar A, Ciulla TA. Genetics of diabetic retinopathy, a leading cause of irreversible blindness in the industrialized world. Genes (Basel). 2021; 12 (8): 1200. doi: 10.3390/genes12081200
12. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020; 37: 101799. doi: 10.1016/j.redox.2020.101799
13. Amoaku WM, Ghanchi F, Bailey C, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond). 2020; 34 (Suppl 1): 1–51. doi: 10.1038/s41433-020-0961-6
14. Neroev V.V., Zaytseva O.V., Balatskaya N.V., Lazutova A.A. Local and systemic production of 45 cytokines in complicated proliferative diabetic retinopaty. Medical immunology (Russia). 2020; 22 (2): 301–10 (In Russ.). https://doi.org/10.15789/1563-0625-LAS-1802
15. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004 Aug; 25 (4): 581–611. doi: 10.1210/er.2003-0027
16. Lipatov D.V., Smirnova N.B., Aleksandrova V.K. Modern algorithm of laser coagulation of the retina in diabetic retinopathy. Sakharnyy diabet. 2007; 10 (3): 45–6 (In Russ.). https://doi.org/10.14341/2072-0351-5997
17. Clinical guidelines. Diabetes mellitus: diabetic retinopathy, diabetic macular edema. Ministry of Health of the Russian Federation. 2023. Accessed 07.05.2025 (In Russ.). https://cr.minzdrav.gov.ru/view-cr/115_2
18. Macaron MM, Al Sabbakh N, Shami MZ, et al. Anti-VEGF injections vs. panretinal photocoagulation laser therapy for proliferative diabetic retinopathy: A systematic review and meta-analysis. Ophthalmol Retina. 2025; 9 (2): 105–21. doi: 10.1016/j.oret.2024.08.004
19. Zhang W, Geng J, Sang A. Effectiveness of panretinal photocoagulation plus intravitreal anti-VEGF treatment against PRP alone for diabetic retinopathy: A systematic review with meta-analysis. Front Endocrinol (Lausanne). 2022; 13: 807687. doi: 10.3389/fendo.2022.807687
20. Yin H, Zhong S. Efficacy of ranibizumab combined with photocoagulation for diabetic retinopathy: A meta-analysis study. Medicine (Baltimore). 2023; 102 (31): e34170. doi: 10.1097/MD.0000000000034170
21. Writing Committee for the Diabetic Retinopathy Clinical Research Network; Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous Ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. AMA. 2015; 314 (20): 2137–46. doi: 10.1001/jama.2015.15217. Erratum in: JAMA. 2016 Mar 1;315(9):944. doi: 10.1001/jama.2016.1591
22. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015; 122 (2): 367–74. doi: 10.1016/j.ophtha.2014.08.048
23. Sadiq MA, Hassan M, Soliman MK, et al. Effects of two different doses of ranibizumab on diabetic retinopathy severity. Ophthalmol Retina. 2017 Nov-Dec; 1 (6): 566–7. doi: 10.1016/j.oret.2017.03.002
24. Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018; 136 (10): 1138–48. doi: 10.1001/jamaophthalmol.2018.3255
25. Fragiotta S, Bassis L, Abdolrahimzadeh B, et al. Exploring current molecular targets in the treatment of neovascular age-related macular degeneration toward the perspective of long-term agents. Int J Mol. Sci. 2024; 25 (8): 4433. https://doi.org/10.3390/ijms25084433
26. Voskresenskaya A.A., Sarkizova M.B., Khodzhaev N.S., et al. Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology. Russian annals of ophthalmology. 2025; 141 (2): 106–16 (In Russ.). https://doi.org/10.17116/oftalma2025141021106
27. Ivanov R., Sekareva G., Kravtsova O., et al. Rules for conducting studies of biosimilar drugs (bioanalogues). Farmakokinetika i farmakodinamika. 2014; 1: 21–36 (In Russ.).
28. ГState Register of Medicines. Instructions for use of the drug Laxolan. Link active as of 11.06.2025. Accessed 16.12.2024 (In Russ.). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b2d1ada9-4b0f-4f8d-b3e0-88a50c6d12e6
29. Shadrichev F.E., Demidova T.Yu., Grigorieva N.N., Kozhevnikov A.A. Prevention of blindness in diabetes mellitus. From laser coagulation of the retina to pharmacology. Farmateka. 2019; 26 (4): 68–78 (In Russ.). https://dx.doi.org/10.18565/pharmateca.2019.4.68-78
30. Shadrichev F.E. Protocol of ophthalmological management of patients with diabetes mellitus. Oftal’mologicheskiye vedomosti. 2008; 1 (2): 54–61 (In Russ.).
31. International Council of Ophthalmology (ICO). ICO Guidelines for Diabetic Eye Care. Int Counc Ophthalmol. 2017. https://vrsp.org.ph/wp-content/uploads/2018/08/ICOGuidelinesforDiabeticEyeCare.pdf
32. Xiao A, Zhou Q, Shao Y, Zhong HF. Effect of intravitreal injection of ranibizumab on retinal ganglion cells and microvessels in the early stage of diabetic retinopathy in rats with streptozotocin-induced diabetes. Exp Ther Med. 2017 Jun; 13 (6): 3360–8. doi: 10.3892/etm.2017.4431
33. Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A position statement by the American Diabetes Association. Diabetes Care. 2017 Mar; 40 (3): 412–8. doi: 10.2337/dc16-2641
Review
For citations:
Malakhova A.I., Bystrevskaya A.A. Combination therapy of proliferative diabetic retinopathy using the Russian biosimilar ranibizumab. Russian Ophthalmological Journal. 2025;18(3):113-120. (In Russ.) https://doi.org/10.21516/2072-0076-2025-18-3-113-120
Views:
6
Email this article 